Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer
- Registration Number
- NCT00726180
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Brief Summary
The majority pf breast cancers present as ER-positive, many of which are able to be targeted with multiple hormonal therapies. Altering ER-negative tumors to increase ER expression has the potential to benefit patients by making hormonal therapies a therapeutic option and possibly improving their overall prognosis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- Female
- Target Recruitment
- 1
-
Women who have Her-2 positive and ER- negative or ER-low breast cancer that has not metastasized, or spread to other parts of the body, are eligible for the study.
-
Participants must have had either a core biopsy or incisional biopsy of their breast cancer, but not yet had definitive breast surgery, including lumpectomy or mastectomy.
-
Participants may not have had a BRCA mutation found on genetic testing.
-
Participants should have not yet received treatment for their breast cancer, including:
- chemotherapy,
- hormonal therapy,
- trastuzumab.
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Treatment arm trastuzumab (Herceptin®) -
- Primary Outcome Measures
Name Time Method Standard Immunohistochemistry and Allred Scores Were to be Used to Measure the Estrogen Receptor (ER) Response Rate in Patients With ER-negative/Low, and Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-positive Breast Cancer. 90 days
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University of Michigan Comprehensive Cancer Center
🇺🇸Ann Arbor, Michigan, United States